[IgIV at home:experience of a center--economic aspects].

Abstract

BACKGROUND:

Intravenous Human immunoglobulin (IVIg) administration is a safe and efficacious treatment in IgG deficiency and auto-immune diseases. The most of the patients treated in hospital ask for home treatment.

MATERIAL AND METHODS:

[corrected] Two cost studies were performed: on study comparing the cost of IVIg in hospital and at home in auto-immune diseases and another evaluating the cost of SCIg and IVIg in hospital and at home in immune deficiency.

RESULTS:

The Home treatment by the IVIg is possible with a care society and safe. Any serious adverse events is occurred, because of a good selection of the patients. The total cost of IVIg seems to be cheaper at home than the hospital treatment with IVIg and home treatment with SCIg.

CONCLUSION:

The home IVIg substitution is possible. This alternative can be proposed at the patient with a stable clinical status, according to his hope and the wish of his family. This alternative is interesting for the life quality and the cost.

• Authors: E Hachulla
• Journal: La Revue de medecine interne (Rev Med Interne) Vol. 28 Spec No. 1 Pg. 7-10 (May 2007) ISSN: 0248-8663 [Print] France
• Vernacular Title: IgIV à domicile: expérience d'un centre--aspects économiques.
• PMID: 17768832 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Immunoglobulins, Intravenous
• Immunologic Factors

Topics

• Autoimmune Diseases (drug therapy, economics)
• France
• Home Infusion Therapy (economics, methods)
• Humans
• Immunoglobulins, Intravenous (economics, therapeutic use)
• Immunologic Factors (economics, therapeutic use)
• Quality of Life
• Self Administration